依折麦布+他汀类药物：获益不足。
Ezetimibe + statin: insufficient benefit.
出版信息
Prescrire Int. 2016 Oct;25(175):245-246.
PMID:30645833
Abstract
After an acute coronary syndrome, the 6-year results of the "IMPROVE-IT" randomized trial showed a 1.6% reduction in the number of nonfatal myocardial infarctions with the ezetimibe + simvastatin combination compared with simvastatin alone, but no reduction in mortality.
摘要
急性冠状动脉综合征后，“改善-IT”随机试验的6年结果显示，与单用辛伐他汀相比，依折麦布+辛伐他汀联合用药可使非致死性心肌梗死数量减少1.6%，但死亡率未降低。
Zotero 插件